{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:08Z","timestamp":1791489668382,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Global Services, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03159-x","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:03:33Z","timestamp":1742288613000},"page":"2298-2313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-Tablet Combination Therapy of Macitentan\/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A\u00a0DUE Phase\u00a03 Trial"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-7701","authenticated-orcid":false,"given":"Fenling","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-0891","authenticated-orcid":false,"given":"Stacy","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0117-7169","authenticated-orcid":false,"given":"Claire","family":"Burbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-6723","authenticated-orcid":false,"given":"Kelly","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7318-3918","authenticated-orcid":false,"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-7064","authenticated-orcid":false,"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-160X","authenticated-orcid":false,"given":"J\u00f6rg","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rafalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro Agustin","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-7013","authenticated-orcid":false,"given":"Jason A.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"3159_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731.","journal-title":"Eur Heart J"},{"key":"3159_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1750-1172-8-97","volume":"8","author":"D Montani","year":"2013","unstructured":"Montani D, Gunther S, Dorfmuller P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013;8:97.","journal-title":"Orphanet J Rare Dis"},{"key":"3159_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164\u201372.","journal-title":"Circulation"},{"key":"3159_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/14017431.2014.931595","volume":"48","author":"D Kylhammar","year":"2014","unstructured":"Kylhammar D, Persson L, Hesselstrand R, Radegran G. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension. Scand Cardiovasc J. 2014;48:223\u201333.","journal-title":"Scand Cardiovasc J"},{"key":"3159_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1164\/rccm.201209-1640OC","volume":"188","author":"AR Tonelli","year":"2013","unstructured":"Tonelli AR, Arelli V, Minai OA, et al. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188:365\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3159_CR6","first-page":"A5636","volume":"205","author":"E Ibrahim","year":"2022","unstructured":"Ibrahim E, Al-Akabawi A, Dawodu M, Ling J, Wang I, Millson B. Concomitant medication use in treatment journey of pulmonary arterial hypertension patient: a Canadian retrospective claims analysis. Am J Respir Crit Care Med. 2022;205:A5636.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"3159_CR7","first-page":"A138","volume":"24","author":"JA Su\u00e1rez","year":"2017","unstructured":"Su\u00e1rez JA, Manzaneque A, Garcia NC, Creus MT, Mir JB. DI-058 Risk of drug\u2013drug interactions in a pulmonary arterial hypertension population. Eur J Hosp Pharm. 2017;24(Suppl 1):A138\u20139.","journal-title":"Eur J Hosp Pharm"},{"key":"3159_CR8","doi-asserted-by":"publisher","first-page":"204589321774361","DOI":"10.1177\/2045893217743616","volume":"8","author":"D Grady","year":"2018","unstructured":"Grady D, Weiss M, Hernandez-Sanchez J, Pepke-Zaba J. Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. Pulm Circ. 2018;8:2045893217743616.","journal-title":"Pulm Circ"},{"key":"3159_CR9","doi-asserted-by":"publisher","first-page":"00299","DOI":"10.1183\/23120541.00299-2020","volume":"6","author":"B Kjellstr\u00f6m","year":"2020","unstructured":"Kjellstr\u00f6m B, Sandqvist A, Hjalmarsson C, Nisell M, N\u00e4sman P, Ivarsson B. Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Res. 2020;6:00299\u20132020.","journal-title":"ERJ Open Res"},{"key":"3159_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40256-022-00553-6","volume":"23","author":"S Qadus","year":"2023","unstructured":"Qadus S, Naser AY, Ofori-Asenso R, Ademi Z, Al Awawdeh S, Liew D. Adherence and discontinuation of disease-specific therapies for pulmonary arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023;23:19\u201333.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3159_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","volume":"83","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig E, Jansa P, Fan F, et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83:473\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"3159_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"3159_CR13","doi-asserted-by":"publisher","first-page":"26152","DOI":"10.3402\/qhw.v9.26152","volume":"9","author":"V Braun","year":"2014","unstructured":"Braun V, Clarke V. What can \u201cthematic analysis\u201d offer health and wellbeing researchers? Int J Qual Stud Health Well-being. 2014;9:26152.","journal-title":"Int J Qual Stud Health Well-being"},{"key":"3159_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903\u201375.","journal-title":"Eur Respir J"},{"key":"3159_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67\u2013119.","journal-title":"Eur Heart J"},{"key":"3159_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0006-2024","volume":"33","author":"A Le Bozec","year":"2024","unstructured":"Le Bozec A, Korb-Savoldelli V, Boiteau C, et al. Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review. Eur Respir Rev. 2024;33:240006.","journal-title":"Eur Respir Rev"},{"key":"3159_CR17","doi-asserted-by":"publisher","first-page":"204589401988008","DOI":"10.1177\/2045894019880086","volume":"10","author":"RP Frantz","year":"2020","unstructured":"Frantz RP, Hill JW, Lickert CA, et al. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. Pulm Circ. 2020;10:2045894019880086.","journal-title":"Pulm Circ"},{"key":"3159_CR18","doi-asserted-by":"publisher","first-page":"A5945","DOI":"10.1016\/j.chest.2023.07.3832","volume":"164","author":"H Farber","year":"2023","unstructured":"Farber H, Germack H, Croteau N, et al. Real-world association between nonadherence to pulmonary arterial hypertension medications and clinical outcomes in the US. Chest. 2023;164:A5945\u20137.","journal-title":"Chest"},{"key":"3159_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77:692\u2013705.","journal-title":"Hypertension"},{"key":"3159_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.36469\/jheor.2024.91396","volume":"11","author":"CJ Paoli","year":"2024","unstructured":"Paoli CJ, Linder J, Gurjar K, Thakur D, Wyckmans J, Grieve S. Effectiveness of single-tablet combination therapy in improving adherence and persistence and the relation to clinical and economic outcomes. J Health Econ Outcomes Res. 2024;11:8\u201322.","journal-title":"J Health Econ Outcomes Res"},{"key":"3159_CR21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1586\/erc.10.137","volume":"8","author":"ME Pugh","year":"2010","unstructured":"Pugh ME, Hemnes AR. Pulmonary hypertension in women. Expert Rev Cardiovasc Ther. 2010;8:1549\u201358.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"3159_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100810","volume":"3","author":"M Saleem","year":"2024","unstructured":"Saleem M, Chowdhury M, Aggarwal A, Aina DA, Zughaib M. Gender differences in the cardiology fellowship interview experience. JACC Adv. 2024;3:100810.","journal-title":"JACC Adv"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03159-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03159-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03159-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:51:05Z","timestamp":1744872665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03159-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3159"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03159-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fenling Fan has served as a scientific committee member for Johnson & Johnson. Stacy Davis, Michael Friberg, J\u00f6rg Linder, and Alvaro Agustin Rodriguez are employees of Johnson & Johnson. Michael Friberg is an employee of Janssen-Cilag Limited and owns shares of stock\/stock options in Johnson & Johnson. Jason Randall, Claire Burbridge, Jennifer Rafalski, and Melanie Hughes have no financial interests to declare. Jason Randall, Claire Burbridge, and Melanie Hughes are employees of Clinical Outcomes Solutions. Jennifer Rafalski was an employee of Clinical Outcomes Solutions at the time that this research was conducted. J\u00f6rg Linder is an employee of Janssen-Cilag GmbH and own shares of stock\/stock options in Johnson & Johnson. Kelly Chin has served as a scientific committee member for Johnson & Johnson; has received research grants\/support from Johnson & Johnson, Altavant, United Therapeutics, Pfizer, Merck, and Gossamer Bio; has received support for travel to meetings from Johnson & Johnson; and has received consultancy fees from Johnson & Johnson, Altavant, United Therapeutics, Gossamer Bio, and Merck. Ekkehard Gr\u00fcnig received research grants to his institution from Acceleron, Actelion, Aerovate, Ferrer, Gossamer, Insmed, Janssen, Keros, Liquidia, Merck, MSD, Novartis, OMT, United Therapeutics; consultancy fees from Actelion, Ferrer, Janssen, Merck, MSD; speaker honoraria from Actelion, Ferrer, Janssen, Merck, MSD; participation on advisory board for Actelion, Ferrer, MSD. Pavel Jansa received consulting fees and grants from Janssen Pharmaceutical Companies of Johnson & Johnson, AOP Orphan Pharmaceuticals, and MSD; participates in a Data Safety Monitoring Board or Advisory Board for Janssen Pharmaceutical Companies of Johnson & Johnson and AOP Orphan Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in compliance with Good Clinical Practice, including the International Conference on Harmonization Guidelines, and consistent with the Declaration of Helsinki 1964 and its later amendments. In addition, the study followed all applicable local laws and regulatory requirements relevant to the conduct of qualitative research. Ethical approval for this sub-study was obtained by clinical study sites in each country; the trial protocol was updated to include the interviews sub-study and ethical approval was granted for this protocol amendment (Supplementary Table\u00a0S3). All patients were required to sign and date the interviews sub-study informed consent form (ICF) before taking part in the interview. This ICF included a Declaration of Helsinki specific to each country. Patients also provided verbal confirmation of consent at the time of the interview. The clinician\u2019s verbal consent was collected during the interview. Participants provided informed consent for their quotes to be used when reporting results. The ICF stated that quotes from the interviews will be used while reporting results and will be associated with the participants unique identification number that they were assigned in the A\u00a0DUE main study. In addition, patients provided verbal confirmation of consent at the time of the interview. The clinician\u2019s verbal consent was collected during the interview.\u00a0Participants provided informed consent for their quotes to be used when reporting results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}